Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-014721
Filing Date
2025-06-11
Accepted
2025-06-11 16:30:51
Documents
19
Period of Report
2025-06-11

Document Format Files

Seq Description Document Type Size
1 DEF 14A formdef14a.htm   iXBRL DEF 14A 664737
2 GRAPHIC proxy_001.jpg GRAPHIC 329043
3 GRAPHIC proxy_002.jpg GRAPHIC 205492
  Complete submission text file 0001641172-25-014721.txt   2730646

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE gtbp-20241231.xsd EX-101.SCH 7205
5 XBRL DEFINITION FILE gtbp-20241231_def.xml EX-101.DEF 12029
6 XBRL LABEL FILE gtbp-20241231_lab.xml EX-101.LAB 70637
7 XBRL PRESENTATION FILE gtbp-20241231_pre.xml EX-101.PRE 44197
22 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 159769
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40023 | Film No.: 251040457
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)